Dmitry Kravchenko graduated on 2010:From the Sechenov Moscow Medical Academy cum laude (diploma number BCA 0733875).
2010 – 2012: residency on oncology, department of radiosurgery of the Blokhin Cancer Research Center.
2012 – 2017: post-graduate research.
2018: defended a thesis (PhD) on “features of adjuvant hormonal therapy in young breast cancer patients”.
2018 – 2019: worked as a chemotherapist in a consult department of the Blokhin Cancer Research Center.
2019 – currently: works as a chemotherapist in a chemotherapy department of the Blokhin Cancer Research Center.
Specialization: breast, ovarian, gastric and colorectal cancer.
Symposia attended as a speaker:
29.03.2019 - V annual Russian Head-and-Neck Congress (“febrile neutropenia prophylaxis”).
Speaks Russian (native), English (C2), Spanish (C2), Italian (C1), Portuguese (B2), French (A2).
Professional interests: cancer targeted and immunotherapy.
Breast cancer (BC) keeps being the most predominant malignant disease in women. In recent years, a trend towards “rejuvenescence” of the malady has been observed that affects its features. Despite modern methods of diagnosis and complex treatment used in young patients, survival rates in this age group are inferior that’s associated with biological and morphological peculiarities of BC in young age. Gradually are being collected data according to what age might be an independent factor exacerbating prognosis. For BC patients younger 40 years, various aspects of adjuvant therapy remain ambiguous: prolonged tamoxifen use, aromatase inhibitors prescription, BRCA profiling, ovarian function suppression, a role of chemotherapy-induced amenorrhea in prognosis, fertility and social concerns. The issue of appropriate, personalized adjuvant hormone therapy of BC is complex and heterogenous that requires a necessity to further conduct international randomized trials.
Key words: breast cancer, young age, endocrine therapy, chemotherapy, BRCA, ovarian suppression